abstract |
The present invention relates generally to the use of human IL-18, also known as interferon-Ϝ-inducing factor (IGIF), in the treatment of skin wounds, surgical wounds, leg ulcers, diabetic ulcers, gastrointestinal mucositis, oral mucositis, and lung injury. |